LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | AZD7762 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1341 | 4168 | 0.3216 | -0.0285 |
| SK-BR-3 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1289 | 4168 | 0.3097 | -0.0518 |
| SK-BR-3 | AT-7519 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 2511 | 4168 | 0.6031 | 0.4499 |
| SK-BR-3 | AZD7762 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1526 | 4168 | 0.3660 | 0.0552 |
| SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1460 | 4168 | 0.3504 | 0.0264 |
| SK-BR-3 | AZD8055 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1306 | 4168 | 0.3138 | -0.0436 |
| SK-BR-3 | Seliciclib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3923 | 4245 | 0.9229 | 0.9004 |
| SK-BR-3 | Seliciclib | 10 | uM | LJP5 | 72 | hr | 1401 | 2209 | 4245 | 0.5182 | 0.3213 |
| SK-BR-3 | AT-7519 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 953 | 4168 | 0.2287 | -0.2181 |
| SK-BR-3 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1907 | 4168 | 0.4574 | 0.2158 |
| SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1020 | 4168 | 0.2452 | -0.1849 |
| SK-BR-3 | AZD7762 | 10 | uM | LJP6 | 72 | hr | 1401 | 856 | 4168 | 0.2056 | -0.2694 |
| SK-BR-3 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1438 | 4168 | 0.3455 | 0.0170 |
| SK-BR-3 | AZD8055 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1361 | 4168 | 0.3270 | -0.0182 |
| SK-BR-3 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4169 | 4245 | 0.9826 | 0.9786 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4234 | 4245 | 0.9990 | 1.0004 |
| SK-BR-3 | Seliciclib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3763 | 4245 | 0.8864 | 0.8542 |
| SK-BR-3 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3235 | 4245 | 0.7609 | 0.6836 |
| SK-BR-3 | AT-7519 | 0.12 | uM | LJP6 | 72 | hr | 1401 | 1469 | 4168 | 0.3528 | 0.0307 |
| SK-BR-3 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1174 | 4168 | 0.2819 | -0.1064 |
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 711 | 4168 | 0.1708 | -0.3524 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1401 | 486 | 4168 | 0.1167 | -0.4930 |
| SK-BR-3 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1112 | 4168 | 0.2665 | -0.1380 |
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3852 | 4168 | 0.9237 | 0.9010 |
| SK-BR-3 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1401 | 443 | 4168 | 0.1063 | -0.5192 |